1. Home
  2. OCFC vs TRVI Comparison

OCFC vs TRVI Comparison

Compare OCFC & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OceanFirst Financial Corp.

OCFC

OceanFirst Financial Corp.

N/A

Current Price

$16.74

Market Cap

1.7B

Sector

Finance

ML Signal

N/A

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

N/A

Current Price

$13.34

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OCFC
TRVI
Founded
1902
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
OCFC
TRVI
Price
$16.74
$13.34
Analyst Decision
Buy
Strong Buy
Analyst Count
7
11
Target Price
$21.42
★ $28.18
AVG Volume (30 Days)
1.1M
★ 2.5M
Earning Date
10-27-2026
11-12-2026
Dividend Yield
★ 4.85%
N/A
EPS Growth
N/A
★ 31.91
EPS
★ 0.27
N/A
Revenue
N/A
N/A
Revenue This Year
$47.45
N/A
Revenue Next Year
$27.01
N/A
P/E Ratio
$61.15
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.60
$9.82
52 Week High
$20.61
$20.22

Technical Indicators

Market Signals
Indicator
OCFC
TRVI
Relative Strength Index (RSI) 49.20 47.88
Support Level $16.16 $13.08
Resistance Level $16.98 $13.55
Average True Range (ATR) 0.36 0.67
MACD 0.16 0.18
Stochastic Oscillator 81.13 92.05

Price Performance

Historical Comparison
OCFC
TRVI

About OCFC OceanFirst Financial Corp.

OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: